Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print May 28, 2008, doi:10.1212/01.wnl.0000303973.71803.81)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow CME: Take the course for this article:
 Volume 71, Number 2, July 8, 2008
Right arrow All Versions of this Article:
01.wnl.0000303973.71803.81v1
71/2/85    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Ringman, J. M.
Right arrow Articles by Cummings, J. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ringman, J. M.
Right arrow Articles by Cummings, J. L.
Received July 20, 2007
Accepted November 8, 2007

Biochemical markers in persons with preclinical familial Alzheimer disease

J. M. Ringman MD*, S. G. Younkin MD, PhD, D. Pratico MD, W. Seltzer PhD, G. M. Cole PhD, D. H. Geschwind MD, PhD, Y. Rodriguez-Agudelo PhD, B. Schaffer MA, J. Fein MA, S. Sokolow PhD, E. R. Rosario PhD, K. H. Gylys PhD, A. Varpetian MD, L. D. Medina BA, and J. L. Cummings MD

From Alzheimer Disease Research Center, UCLA Department of Neurology (J.M.R., G.M.C., D.H.G., B.S., L.D.M., J.L.C.), School of Nursing (J.F., S.S., K.H.G.), and Department of Medicine (E.R.R.), University of California, Los Angeles; Department of Pharmacology (S.G.Y.), Mayo Clinic, Jacksonville, FL; Department of Pharmacology (D.P.), Temple University, Philadelphia, PA; Athena Diagnostics, Inc. (W.S.), Worcester, MA; Greater Los Angeles Veterans Affairs Geriatric Research (G.M.C.), Education, and Clinical Center; National Institute of Neurology and Neurosurgery (Y.R.-A.), Mexico City, Mexico; and Department of Neurology (A.V.), Keck School of Medicine, USC, Rancho Los Amigos National Rehabilitation Center, Downey, CA.


* To whom correspondence should be addressed. E-mail: jringman{at}mednet.ucla.edu.

Background: Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease.

Methods: Twenty-one subjects at risk for presenilin-1 (n = 17) or amyloid precursor protein (n = 4) mutations underwent evaluation with the Clinical Dementia Rating (CDR) scale. We obtained plasma from all subjects and CSF from 11. Plasma (A{beta}40, A{beta}42, F2-isoprostanes) and CSF (F2-isoprostanes, t-tau, p-tau181, A{beta}40, A{beta}42, and A{beta}42/A{beta}40 ratio) levels were compared between FAD mutation carriers (MCs) and noncarriers (NCs).

Results: Plasma A{beta}42 levels (25.1 pM vs 15.5 pM, p = 0.031) and the ratio of A{beta}42/A{beta}40 (0.16 vs 0.11, p = 0.045) were higher in presymptomatic MCs. Among MCs, those with CDR scores of 0.5 had lower plasma A{beta}42 levels than those with CDR scores of 0 (14.1 pM vs 25.1, p = 0.02). The ratio of A{beta}42 to A{beta}40 was also reduced in the CSF (0.08 vs 0.15, p = 0.046) of nondemented MCs compared to NCs. Total CSF tau and p-tau181 levels were elevated in presymptomatic FAD MCs. CSF levels of F2-isoprostanes were also elevated in MCs (n = 7, 48.6 pg/mL) compared to NCs (n = 4, 21.6 pg/mL, p = 0.031).

Conclusions: Our data indicate that A{beta}42 is elevated in plasma in familial Alzheimer disease (FAD) mutation carriers (MCs) and suggests that this level may decrease with disease progression prior to the development of overt dementia. We also demonstrated that the ratio of A{beta}42 to A{beta}40 was reduced in the CSF of nondemented MCs and that elevations of t-tau and p-tau181 are sensitive indicators of presymptomatic disease. Our finding of elevated F2-isoprostane levels in the CSF of preclinical FAD MCs suggests that oxidative stress occurs downstream to mismetabolism of amyloid precursor protein.




This article has been cited by other articles:


Home page
 NeurologyHome page
J. Quinn and M. N. Sabbagh
Detecting Alzheimer disease before it happens: The key to prevention?
Neurology, July 8, 2008; 71(2): 78 - 79.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.